An alternative to mRNA-based coronavirus vaccines has received an Emergency Use Authorization (EUA) in the USA, providing a new option for a first booster dose.
Developed by US biotech Novavax (Nasdaq: NVAX) and marketed elsewhere as Nuvaxovid, the recombinant, adjuvanted jab has been created using a more traditional vaccine technology.
While rates of vaccination are high in the USA, interest in booster jabs has waned as the first waves of the pandemic recede. Novavax may hope to access part of the market which is skeptical about newer, mRNA-based vaccine technologies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze